EVR 6.7MSFT 0.71DAL 0.73JPM 10.04ATD.TO 0.76MTD 11.16CRWD -28.52
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.69
+0.35 (1.38%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing significant challenges, primarily due to a patent cliff and a lack of earnings momentum following the COVID-19 pandemic. Many experts express concerns over its drug pipeline, indicating that the company is in need of a blockbuster drug to drive future growth. While it maintains an attractive dividend yield—ranging from 6.4% to 7%—there is skepticism about the sustainability of this yield if new profitable drugs are not developed soon. The stock’s valuation is seen as low, trading at around 8-10 times earnings, which some experts believe might make it appealing for patient investors. However, the consensus also points to caution due to the industry-wide challenges, including cost-cutting measures and potential government pressure on drug pricing.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
PAST TOP PICK

Pfizer Inc(PFE)

Nov 23, 2005
(A Top Pick Sept 7/05. Down 18%.) His model is still showing a 50% upside. Still likes.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$21.64

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 22, 2005
There are law suits coming at these companies from different directions. Merck (MRK-N) just got hit with a massive lawsuit in Texas and this has put a big pall over the industry. However, the demograpohics in this industry are fabulous. This one is the biggest in the industry and they have a huge amount of cash on their balance sheet. The options are very cheap and not a bad way to go.
Photo of Richard CroftRichard Croft
No
Unlock Rating
$21.38

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 14, 2005
Not a fan of the big drug companies. They are under tremendous pressure. One of the biggest expenses the US has to grapple with is health care, so the government is now on the side of the consumer, so it would be very hard for big pharma to have the kind of margins and sales growth they used to have.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$22.25

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 02, 2005
The overall pharmaceutical industry has had a tough time. Yields almost 4%. Trading at close to 10 X earnings. This industry has had bad direction from the FDA. Great balance sheet and lots of free cash flow.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$21.60

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 26, 2005
The ethical drug companies continue to have a very difficult time. You are seeing a classic compression of the price/earnings multiple. The growth rate of these companies has gone from 25% growth to almost 0% growth in the last 3/4 years.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$21.06

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Oct 20, 2005
There's a possibility for it to go to $19.65 at which time he will buy more. It's in a bottoming process. Looking for the new earnings estimates to come in during the next few weeks. His model price is $36 which is a 51% differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$21.90

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 13, 2005
Have too many suits hanging over him for his tastes. Doesn't like a sector where there's a lot of potential for a lot of nasty surprises.
Photo of Ross HealyRoss Healy
No
Unlock Rating
$24.50

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 27, 2005
Doesn't feel the FDA hasn't done a good job, but that is changing. Feels the pharmaceutical industry's pipeline is being valued at a very low multiple. At one of the cheapest levels in the last 10 years. Yields about 2.5/3%. Throws off tons of free cash flow. A long term story.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$24.80

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 22, 2005
Drug stars such as Pfizer (PFE-N) Merck (MRK-N), etc. are attractively valued but are clearly out of favour. They have great long term track records and are in strong financial positions, however, there is a lack of predictability regarding the science. Doesn't like the cash flow dynamics where they spend billions up front with no sure win ahead. Litigation risks.
Photo of James Cole, BA, CFAJames Cole, BA, CFA
Owned
Unlock Rating
$25.25

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 21, 2005
Still likes and is a believer in this company. His model price is 50% above the current price, but doesn't know when that value will be recognized.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.31

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 20, 2005
No advantage to be in this stock. The whole drug area has changed in the last few years and they are not as strong as they once were. The market seems to be moving more to generics.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$25.40

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 07, 2005
His model price is $37.65, an 46% differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.51

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 31, 2005
Very cheap on the numbers, but they have a patent issue on their largest drug, Lippitor. If they lost Lippitor, you would be looking at a stock below $20 overnight. There's a lot of risk in the name.
Photo of Brad WillockBrad Willock
No
Unlock Rating
$25.48

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2005
Have recently added this to his fund. Good free cash flow, strong balance sheet. There is some risk right now with their Lipitor drug. A group in India is making a generic version.
Photo of Peter HofstraPeter Hofstra
Owned
Unlock Rating
$25.36

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Aug 12, 2005
Have done a lot of restructuring. Will cut their costs which will help. Part of the problem in the pharmaceutical industry has been the poor leadership in the FDA. A cheap stock and you're getting paid a 3.5% yield. Trades at a very low multiple.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$26.16

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 646 to 660 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO 5.13$270.94
BHP -2.07$88.78
TA.TO -2.08$18
V 7.78$320.18
TOU.TO -0.12$65.42

Today's Top Picks

EVR 6.7$346.79
MSFT 0.71$428.05
DAL 0.73$79.51
JPM 10.04$310.89
ATD.TO 0.76$80.79

Popular Articles

Latest Sell Signals

PRL.TO 0.07$21.2
CNQ.TO -0.14$66.22
SHOP.TO 4.46$161.54
RIO -2.46$105.4
BB.TO 0.3$14.4

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica